Pharma stocks fell once again on June 17, marking their 3rd drop in the last 4 sessions. It’s a tough time for the sector. Sun Pharma, Aurobindo, Granules, Lupin — all fell up to 3.3%.
The Nifty Pharma index was down nearly 1.5%. It fell to 21,711 and become the worst-performing sector of the day.
Sun Pharma Leads the Fall
Sun Pharma fell over 2%. It traded at ₹1,649 and was the top loser on the Sensex. The US FDA recently issued eight observations on its Halol plant in Gujarat. That worried many investors and made them sell their holdings.
Aurobindo fell nearly 3.3%. Granules was down about 3%. Lupin, Natco, and Ajanta fell more than 2%. It seemed like the whole sector was under pressure.
Other Players Also Fell
Other big names like Divi’s Laboratories, Zydus Life, Laurus Labs, and Cipla fell over 1.6%. Alkem, Dr Reddy’s, IPCA, Torrent, Glenmark, and Abbott were in the red with small losses.
Meanwhile, Mankind fell more than 1%. The selling was broad and weak sentiment seemed to affect nearly all companies.
Also Read Mega Market Shake-up! Vishal Mega Mart Plunges 7% After ₹10,488 Cr Block Deal
Some Gained, Few Held Strong
It wasn’t all bad. Gland Pharma jumped nearly 1.4%. Biocon remained in the green with small gains. It shows not all stocks move in the same direction — some find their own path.
How Tariffs Played a Part
Pharma stocks fell after US President Trump raised the alarm about possible tariffs on drugs back in April. Although the first round of taxes was delayed and a deal seemed close, the fear remained. Trump has a deadline of 9th of July to decide whether to put the tariff into action.
This uncertainty made many traders nervous and prone to selling their stocks quickly.
Looking Forward
Pharma stocks will likely stay volatile in the coming days. Until the US clarifies its policy, investors will remain nervous. Nonetheless, many traders say these drops can be a buying opportunity for the long term — if you believe in the companies’ fundamentals.
Pharma stocks are under pressure, and the market mood is weak. But it’s not all black and white. Some companies are holding strong, while others are feeling the pinch.
With US policy up in the air and earnings reports due soon, this story is far from over.
So stay vigilant, watch the signals, and be ready to grab opportunities when you find them.
Also Read Mazagon Dock Up, BDL Gains 4%: Defence Stocks Outperform Nifty Amid War Risks
